Vaccines for COVID-19 – Can we avoid living again in a ghost town?

Vacunas para COVID-19 - ¿Podemos evitar volver a vivir en un pueblo fantasma?

dc.creatorRodriguez-Morales, Alfonso J.
dc.creatorMáttar, Salim
dc.creatorGonzález T, Marco
dc.date2021-03-16
dc.date.accessioned2022-12-15T14:43:41Z
dc.date.available2022-12-15T14:43:41Z
dc.identifierhttps://revistamvz.unicordoba.edu.co/article/view/e2350
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5353474
dc.descriptionOver the last year, the pandemic of Coronavirus Disease 2019 (COVID-19), caused by the Severe Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), have caused considerable havoc on society (1). Indeed, this has been a chronicle of an announced zoonosis (2,3). Its impact has been even deeper in developing countries (4,5), such as Colombia (6,7,8). So far, up to March 9, 2021, the world has recorded 117.5 million cases of COVID-19, with 2.6 million deaths (2.22%). Colombia is included in the Top 20 countries with the highest number of cases (2.282.372) and the Top 20 deaths globally (60.676).en-US
dc.descriptionDurante el último año, la pandemia de la Enfermedad por Coronavirus 2019 (COVID-19), causada por el Síndrome Respiratorio Severo Coronavirus 2 (SARS-CoV-2), ha causado estragos considerables en la sociedad (1). De hecho, esta ha sido una crónica de una zoonosis anunciada (2,3). Su impacto ha sido aún más profundo en países en desarrollo (4,5), como Colombia (6,7,8). Hasta el momento, hasta el 9 de marzo de 2021, el mundo ha registrado 117.5 millones de casos de COVID-19, con 2.6 millones de muertes (2.22%). Colombia está incluida en el Top 20 de países con el mayor número de casos (2.282.372) y en el Top 20 de muertes a nivel mundial (60.676).es-ES
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.formatapplication/zip
dc.formatapplication/zip
dc.formatapplication/xml
dc.formatapplication/xml
dc.formataudio/mpeg
dc.formataudio/mpeg
dc.languagespa
dc.languageeng
dc.publisherUniversidad de Córdobaes-ES
dc.relationhttps://revistamvz.unicordoba.edu.co/article/view/e2350/2874
dc.relationhttps://revistamvz.unicordoba.edu.co/article/view/e2350/2875
dc.relationhttps://revistamvz.unicordoba.edu.co/article/view/e2350/3304
dc.relationhttps://revistamvz.unicordoba.edu.co/article/view/e2350/3306
dc.relationhttps://revistamvz.unicordoba.edu.co/article/view/e2350/3305
dc.relationhttps://revistamvz.unicordoba.edu.co/article/view/e2350/3307
dc.relationhttps://revistamvz.unicordoba.edu.co/article/view/e2350/2876
dc.relationhttps://revistamvz.unicordoba.edu.co/article/view/e2350/2877
dc.relation/*ref*/1. Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020; 33(4):e00028-20. https://doi.org/10.1177/1470320320926902
dc.relation/*ref*/2. Mattar V S, González Tous M. Emergencia zoonótica por coronavirus: riesgo potencial para la salud pública en America Latina. Rev MVZ Cordoba. 2018; 23(3):6775-6777. https://doi.org/10.21897/rmvz.1408
dc.relation/*ref*/3. Mattar S, González Tous M. Coronavirus: Crónica de una zoonosis anunciada. Rev MVZ Cordoba. 2020;25(2):e2048. https://doi.org/10.21897/rmvz.2048
dc.relation/*ref*/4. Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, Mendez CA, Zambrano LI, Franco-Paredes C, et al. COVID-19 in Latin America: The implications of the first confirmed case in Brazil. Travel Med Infect Dis. 2020; 35:101613. https://doi.org/10.1016/j.tmaid.2020.101613
dc.relation/*ref*/5. Cimerman S, Chebabo A, Cunha CAD, Rodriguez-Morales AJ. Deep impact of COVID-19 in the healthcare of Latin America: the case of Brazil. Braz J Infect Dis. 2020; 24(2):93-95. https://doi.org/10.1016/j.bjid.2020.04.005
dc.relation/*ref*/6. Diaz-Guio DA, Villamil-Gomez WE, Dajud L, Perez-Diaz CE, Bonilla-Aldana DK, Mondragon-Cardona A, et al. Will the Colombian intensive care units collapse due to the COVID-19 pandemic? Travel Med Infect Dis. 2020; 38:101746. https://dx.doi.org/10.1016%2Fj.tmaid.2020.101746
dc.relation/*ref*/7. Mattar S, Martinez-Bravo C, Rivero R, Contreras H, Faccini-Martinez AA, Guzman-Teran C, et al. Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean. Ann Clin Microbiol Antimicrob. 2020; 19:58. https://doi.org/10.1186/s12941-020-00397-5
dc.relation/*ref*/8. Mattar S, Alvis-Guzman N, Garay E, Rivero R, Garcia A, Botero Y, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries? Open Forum Infect Dis. 2020; 7(12):ofaa550. https://doi.org/10.1093/ofid/ofaa550
dc.relation/*ref*/9. Cardona-Ospina JA, Rojas-Gallardo DM, Garzon-Castano SC, Jimenez-Posada EV, Rodriguez-Morales AJ. Phylodynamic analysis in the understanding of the current COVID-19 pandemic and its utility in vaccine and antiviral design and assessment. Hum Vaccin Immunother. 2021; 1-8. https://doi.org/10.1080/21645515.2021.1880254
dc.relation/*ref*/10. Patel SK, Pathak M, Tiwari R, Yatoo MI, Malik YS, Sah R, et al. A vaccine is not too far for COVID-19. J Infect Dev Ctries. 2020; 14(5):450-453. https://doi.org/10.3855/jidc.12744
dc.relation/*ref*/11. Rabaan AA, Al-Ahmed SH, Sah R, Al-Tawfiq JA, Al-Qaaneh AM, Al-Jamea LH, et al. Recent advances in vaccine and immunotherapy for COVID-19. Hum Vaccin Immunother. 2020; 16(12):3011-3022. https://doi.org/10.1080/21645515.2020.1825896
dc.relation/*ref*/12. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5):403-416. https://doi.org/10.1056/NEJMoa2035389
dc.relation/*ref*/13. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2101765
dc.relation/*ref*/14. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-15. https://doi.org/10.1056/NEJMoa2034577
dc.relation/*ref*/15. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021; 397(10278):P952-954. https://doi.org/10.1016/S0140-6736(21)00370-6
dc.relation/*ref*/16. Schlagenhauf P, Patel D, Rodriguez-Morales A, Gautret P, Grobusch MP, Leder K. Variants, Vaccines and Vaccination passports: Challenges and Chances for Travel Medicine in 2021. Travel Med Infect Dis. 2021; 40:101996. https://dx.doi.org/10.1016%2Fj.tmaid.2021.101996
dc.sourceJournal MVZ Cordoba; Vol. 26 No. 2 (2021): Revista MVZ Córdoba Volumen 26(2) Mayo-Agosto 2021; e2350en-US
dc.sourceRevista MVZ Córdoba; Vol. 26 Núm. 2 (2021): Revista MVZ Córdoba Volumen 26(2) Mayo-Agosto 2021; e2350es-ES
dc.source1909-0544
dc.source0122-0268
dc.source10.21897/rmvz.v26.n2.2021
dc.subjectPandemicen-US
dc.subjectCOVID-19en-US
dc.subjectSARS-CoV-2en-US
dc.subjectvaccinesen-US
dc.subjectPandemiaes-ES
dc.subjectCOVID-19es-ES
dc.subjectSARS-CoV-2es-ES
dc.subjectvacunases-ES
dc.titleVaccines for COVID-19 – Can we avoid living again in a ghost town?en-US
dc.titleVacunas para COVID-19 - ¿Podemos evitar volver a vivir en un pueblo fantasma?es-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución